{"id":"https://openalex.org/W2952833147","doi":"https://doi.org/10.1016/j.anai.2019.06.004","title":"Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases","display_name":"Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases","publication_year":2019,"publication_date":"2019-06-20","ids":{"openalex":"https://openalex.org/W2952833147","doi":"https://doi.org/10.1016/j.anai.2019.06.004","mag":"2952833147","pmid":"https://pubmed.ncbi.nlm.nih.gov/31228628"},"language":"en","primary_location":{"id":"doi:10.1016/j.anai.2019.06.004","doi":"https://doi.org/10.1016/j.anai.2019.06.004","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.anai.2019.06.004","pdf_url":"http://www.annallergy.org/article/S1081120619304363/pdf","source":{"id":"https://openalex.org/S153558830","display_name":"Annals of Allergy Asthma & Immunology","issn_l":"1081-1206","issn":["1081-1206","1534-4436"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Allergy, Asthma & Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.annallergy.org/article/S1081120619304363/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058987519","display_name":"Sudhir Gupta","orcid":"https://orcid.org/0000-0001-7422-1453","observed_orcids":["https://orcid.org/0000-0001-7422-1453"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudhir Gupta","raw_affiliation_strings":["University of California at Irvine, Irvine, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California at Irvine, Irvine, California","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032765249","display_name":"Mark R. Stein","orcid":"https://orcid.org/0000-0001-5653-0631","observed_orcids":["https://orcid.org/0000-0001-5653-0631"]},"institutions":[{"id":"https://openalex.org/I4210116253","display_name":"Allergy Associates of the Palm Beaches","ror":"https://ror.org/0388avt91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210116253"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Stein","raw_affiliation_strings":["Allergy Associates of the Palm Beaches, North Palm Beach, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allergy Associates of the Palm Beaches, North Palm Beach, Florida","institution_ids":["https://openalex.org/I4210116253"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Iftikhar Hussain","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Iftikhar Hussain","raw_affiliation_strings":["Allergy, Asthma, and Immunology Center, Tulsa, Oklahoma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allergy, Asthma, and Immunology Center, Tulsa, Oklahoma","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013841219","display_name":"Kenneth Paris","orcid":"https://orcid.org/0000-0003-2496-3947","observed_orcids":["https://orcid.org/0000-0003-2496-3947"]},"institutions":[{"id":"https://openalex.org/I4210117366","display_name":"Children's Hospital of New Orleans","ror":"https://ror.org/02etexs15","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210117366"]},{"id":"https://openalex.org/I75420490","display_name":"Louisiana State University Health Sciences Center New Orleans","ror":"https://ror.org/01qv8fp92","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121820613","https://openalex.org/I75420490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Paris","raw_affiliation_strings":["LSU Health Sciences Center, Children's Hospital of New Orleans, New Orleans, Louisiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LSU Health Sciences Center, Children's Hospital of New Orleans, New Orleans, Louisiana","institution_ids":["https://openalex.org/I4210117366","https://openalex.org/I75420490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070985333","display_name":"Werner Engl","orcid":"https://orcid.org/0000-0002-1705-7850","observed_orcids":["https://orcid.org/0000-0002-1705-7850"]},"institutions":[{"id":"https://openalex.org/I4210156998","display_name":"Takeda (Austria)","ror":"https://ror.org/04nm3yk20","country_code":"AT","type":"company","lineage":["https://openalex.org/I4210156998","https://openalex.org/I44892455"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Werner Engl","raw_affiliation_strings":["The Takeda group of companies, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Takeda group of companies, Vienna, Austria","institution_ids":["https://openalex.org/I4210156998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109323636","display_name":"Barbara McCoy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156998","display_name":"Takeda (Austria)","ror":"https://ror.org/04nm3yk20","country_code":"AT","type":"company","lineage":["https://openalex.org/I4210156998","https://openalex.org/I44892455"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Barbara McCoy","raw_affiliation_strings":["The Takeda group of companies, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Takeda group of companies, Vienna, Austria","institution_ids":["https://openalex.org/I4210156998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052214021","display_name":"Christopher J. Rabbat","orcid":"https://orcid.org/0000-0002-1609-6655","observed_orcids":["https://orcid.org/0000-0002-1609-6655"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher J. Rabbat","raw_affiliation_strings":["The Takeda group of companies, Chicago, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Takeda group of companies, Chicago, Illinois","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058777943","display_name":"Leman Yel","orcid":"https://orcid.org/0000-0001-8357-3186","observed_orcids":["https://orcid.org/0000-0001-8357-3186"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]},{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP","US"],"is_corresponding":true,"raw_author_name":"Leman Yel","raw_affiliation_strings":["University of California at Irvine, Irvine, California; The Takeda group of companies, Cambridge, Massachusetts. Electronic address: leman.yel@takeda.com","The Takeda group of companies, Cambridge, Massachusetts","University of California at Irvine, Irvine, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California at Irvine, Irvine, California; The Takeda group of companies, Cambridge, Massachusetts. Electronic address: leman.yel@takeda.com","institution_ids":["https://openalex.org/I204250578","https://openalex.org/I44892455"]},{"raw_affiliation_string":"The Takeda group of companies, Cambridge, Massachusetts","institution_ids":[]},{"raw_affiliation_string":"University of California at Irvine, Irvine, California","institution_ids":["https://openalex.org/I204250578"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5058777943"],"corresponding_institution_ids":["https://openalex.org/I204250578","https://openalex.org/I44892455"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":0.0969,"has_fulltext":true,"cited_by_count":4,"citation_normalized_percentile":{"value":0.36701885,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"123","issue":"3","first_page":"271","last_page":"279.e1"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10634","display_name":"Food Allergy and Anaphylaxis Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/primary-immunodeficiency","display_name":"primary immunodeficiency","score":0.890999972820282},{"id":"https://openalex.org/keywords/onboarding","display_name":"onboarding","score":0.6589999794960022},{"id":"https://openalex.org/keywords/infusion-rate","display_name":"infusion rate","score":0.6060000061988831},{"id":"https://openalex.org/keywords/infusion-volume","display_name":"infusion volume","score":0.9559999704360962},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.9539999961853027},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9240000247955322},{"id":"https://openalex.org/keywords/patient-experience","display_name":"patient experience","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9583924412727356},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8283997774124146},{"id":"https://openalex.org/C2779019163","wikidata":"https://www.wikidata.org/wiki/Q3043160","display_name":"Primary immunodeficiency","level":3,"score":0.627035915851593},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5575709939002991},{"id":"https://openalex.org/C2779185108","wikidata":"https://www.wikidata.org/wiki/Q7091744","display_name":"Onboarding","level":2,"score":0.47048428654670715},{"id":"https://openalex.org/C2984752397","wikidata":"https://www.wikidata.org/wiki/Q3259956","display_name":"Primary care","level":2,"score":0.43841278553009033},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.34594202041625977},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.33921706676483154},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2309660017490387},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.132457435131073},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.11879011988639832},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.0},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000081207","descriptor_name":"Primary Immunodeficiency Diseases","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000081207","descriptor_name":"Primary Immunodeficiency Diseases","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004361","descriptor_name":"Drug Tolerance","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007136","descriptor_name":"Immunoglobulins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009656","descriptor_name":"North America","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055104","descriptor_name":"Infusions, Subcutaneous","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.anai.2019.06.004","doi":"https://doi.org/10.1016/j.anai.2019.06.004","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.anai.2019.06.004","pdf_url":"http://www.annallergy.org/article/S1081120619304363/pdf","source":{"id":"https://openalex.org/S153558830","display_name":"Annals of Allergy Asthma & Immunology","issn_l":"1081-1206","issn":["1081-1206","1534-4436"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Allergy, Asthma & Immunology","raw_type":"journal-article"},{"id":"pmid:31228628","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31228628","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1016/j.anai.2019.06.004","doi":"https://doi.org/10.1016/j.anai.2019.06.004","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.anai.2019.06.004","pdf_url":"http://www.annallergy.org/article/S1081120619304363/pdf","source":{"id":"https://openalex.org/S153558830","display_name":"Annals of Allergy Asthma & Immunology","issn_l":"1081-1206","issn":["1081-1206","1534-4436"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Allergy, Asthma & Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309705","display_name":"Shire","ror":"https://ror.org/0547dck29"},{"id":"https://openalex.org/F4320310420","display_name":"CSL Behring","ror":"https://ror.org/01jxhxv92"},{"id":"https://openalex.org/F4320311257","display_name":"Baxalta","ror":"https://ror.org/040fqas51"},{"id":"https://openalex.org/F4320329568","display_name":"Grifols","ror":"https://ror.org/02ed64f32"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2952833147.pdf","grobid_xml":"https://content.openalex.org/works/W2952833147.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1979533125","https://openalex.org/W2035488076","https://openalex.org/W2045096978","https://openalex.org/W2049769828","https://openalex.org/W2131200545","https://openalex.org/W2134678353","https://openalex.org/W2139592987","https://openalex.org/W2495752760","https://openalex.org/W2511870232","https://openalex.org/W2519097826","https://openalex.org/W2567251402","https://openalex.org/W2572233504"],"related_works":["https://openalex.org/W2913136187","https://openalex.org/W2901456880","https://openalex.org/W2784135290","https://openalex.org/W2908688134","https://openalex.org/W2784332894","https://openalex.org/W2953941249","https://openalex.org/W4290462614","https://openalex.org/W2912574289","https://openalex.org/W2511870232","https://openalex.org/W2519097826"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1],"subcutaneous":[2],"immune":[3],"globulin":[4],"(SCIG)":[5],"20%":[6],"product,":[7],"Ig20Gly,":[8],"was":[9,149,153],"shown":[10],"to":[11,30,36,52,89],"be":[12],"efficacious":[13],"and":[14,23,33,58,94,105,128,161,166,175,183,211,221,238,247],"well":[15,243],"tolerated":[16,244],"in":[17,39,62,77,171],"2":[18],"phase":[19,74],"2/3":[20,75],"North":[21,64],"American":[22,65],"European":[24],"studies":[25],"at":[26,130,234],"infusion":[27,56,60,95,123,141,157,217,223,231],"volumes":[28,158,239],"up":[29,35,88],"60":[31,37,236],"mL/site":[32,241],"rates":[34,57,160,204,232],"mL/h/site":[38,127,148,237],"patients":[40,79,104,120,144,176],"with":[41,54],"primary":[42],"immunodeficiency":[43],"diseases.":[44],"OBJECTIVE:":[45],"To":[46],"assess":[47],"patient":[48],"experience":[49],"after":[50],"switching":[51],"Ig20Gly":[53,85,230],"fast":[55],"large":[59],"volumes/site":[61],"the":[63,72,100,122,139,172,190],"study.":[66],"METHODS:":[67],"In":[68],"this":[69,131],"analysis":[70],"of":[71,119,125,164,189,192,205,233,251],"open-label":[73],"study":[76,101],"which":[78],"aged":[80],"\u22652":[81],"years":[82],"received":[83],"weekly":[84],"infusions":[86],"for":[87,102,133],"approximately":[90],"1.3":[91],"years,":[92],"tolerability":[93,184],"parameters":[96,182],"were":[97,185,242],"assessed":[98],"throughout":[99,248],"all":[103],"by":[106],"prestudy":[107,193,252],"treatment":[108,194],"regimen":[109],"(intravenous":[110],"[IV]":[111],"switchers":[112,201,210],"or":[113,135,159,196],"SC":[114,197,209,226],"switchers).":[115],"RESULTS:":[116],"Overall,":[117],"61%":[118],"reached":[121,146],"rate":[124,132],"\u226560":[126,147,240],"continued":[129],"1":[134],"more":[136],"subsequent":[137],"infusions;":[138],"median":[140,216],"number":[142],"when":[143],"first":[145],"3.":[150],"No":[151],"association":[152],"found":[154],"between":[155],"higher":[156,215],"increased":[162],"incidences":[163],"local":[165,206],"systemic":[167],"adverse":[168],"events":[169],"(AEs)":[170],"total":[173],"population":[174],"younger":[177],"than":[178,208],"16":[179],"years.":[180],"Infusion":[181],"generally":[186],"comparable":[187],"regardless":[188,250],"route":[191],"(IV":[195],"switchers);":[198],"however,":[199],"IV":[200],"experienced":[202],"lower":[203],"AEs":[207],"had":[212],"a":[213],"slightly":[214],"volume":[218],"per":[219],"site":[220],"longer":[222],"duration":[224],"vs":[225],"switchers.":[227],"CONCLUSION:":[228],"High":[229],"least":[235],"during":[245],"onboarding":[246],"treatment,":[249],"treatment.":[253],"TRIAL":[254],"REGISTRATION:":[255],"ClinicalTrials.gov":[256],"Identifier":[257],"NCT01218438.":[258]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-06-27T00:00:00"}